Matches in SemOpenAlex for { <https://semopenalex.org/work/W3186166064> ?p ?o ?g. }
Showing items 1 to 100 of
100
with 100 items per page.
- W3186166064 endingPage "106671" @default.
- W3186166064 startingPage "106671" @default.
- W3186166064 abstract "Rituximab (chimeric anti-CD20 monoclonal antibody) treatment is approved for chronic lymphocytic leukemia (CLL) and non-Hodgkin lymphoma (NHL). Rituximab-abbs (first biosimilar approved in 2017) is expected to significantly reduce healthcare economic burden due to lower acquisition costs. This non-interventional, non-comparative study assessed real-world effectiveness and tolerability of rituximab-abbs and rituximab in treatment-naive patients with CLL or NHL. Via an online physician survey, 46 UK-registered hematologists and oncologists retrospectively reported on randomly selected patients aged ≥18 years with CLL or NHL with rituximab-abbs or rituximab as first-line immunotherapy. Overall, 201 patient charts were examined across 4 cohorts: rituximab-abbs in CLL, rituximab-abbs in NHL, rituximab in CLL, rituximab in NHL. Demographic profiles across cohorts were similar. Most patients (94 %–100 %) received combination therapy (rituximab-abbs or rituximab mainly with chemotherapy). For both treatments, overall response rate (94 %–98 %) and 1-year overall survival (98 %–100 %) were very high for patients with CLL or NHL. Most common serious adverse events were neutropenia, fatigue, anemia and infusion reactions. The majority of patients (54 %–66 %) did not experience a grade ≥3 adverse event. Healthcare resource utilization was similarly high across cohorts, driven by diagnostic testing, oncologist office visits, and day-case hospital admissions; many patients required supportive medical therapies. Mean annual savings of ∼£1000/patient driven by acquisition costs occurred with rituximab-abbs versus rituximab, administration costs were similar. Rituximab-abbs and rituximab demonstrated similar effectiveness and tolerability in treating CLL and NHL in routine UK clinical practice and demonstrate the utility of the biosimilar as a cost-saving alternative treatment." @default.
- W3186166064 created "2021-08-02" @default.
- W3186166064 creator A5002095623 @default.
- W3186166064 creator A5029953659 @default.
- W3186166064 creator A5048130857 @default.
- W3186166064 creator A5049387929 @default.
- W3186166064 creator A5060985600 @default.
- W3186166064 creator A5070684364 @default.
- W3186166064 creator A5075954179 @default.
- W3186166064 creator A5077832560 @default.
- W3186166064 date "2021-12-01" @default.
- W3186166064 modified "2023-09-25" @default.
- W3186166064 title "Assessment of rituximab-abbs, a biosimilar, and rituximab outcomes in patients with CLL or NHL: A real-world UK study" @default.
- W3186166064 cites W1986159244 @default.
- W3186166064 cites W2082635925 @default.
- W3186166064 cites W2310716991 @default.
- W3186166064 cites W2553911513 @default.
- W3186166064 cites W2606245581 @default.
- W3186166064 cites W2612430891 @default.
- W3186166064 cites W2613658130 @default.
- W3186166064 cites W2734929604 @default.
- W3186166064 cites W2736281699 @default.
- W3186166064 cites W2740132694 @default.
- W3186166064 cites W2781525129 @default.
- W3186166064 cites W2790763558 @default.
- W3186166064 cites W2889646458 @default.
- W3186166064 cites W2898856153 @default.
- W3186166064 cites W2913809318 @default.
- W3186166064 cites W2964876593 @default.
- W3186166064 cites W2966512175 @default.
- W3186166064 cites W2993964230 @default.
- W3186166064 cites W3003670850 @default.
- W3186166064 cites W3016057705 @default.
- W3186166064 cites W3016330984 @default.
- W3186166064 cites W3017160203 @default.
- W3186166064 cites W3084370137 @default.
- W3186166064 cites W3108781725 @default.
- W3186166064 cites W3111223035 @default.
- W3186166064 doi "https://doi.org/10.1016/j.leukres.2021.106671" @default.
- W3186166064 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/34530254" @default.
- W3186166064 hasPublicationYear "2021" @default.
- W3186166064 type Work @default.
- W3186166064 sameAs 3186166064 @default.
- W3186166064 citedByCount "4" @default.
- W3186166064 countsByYear W31861660642022 @default.
- W3186166064 countsByYear W31861660642023 @default.
- W3186166064 crossrefType "journal-article" @default.
- W3186166064 hasAuthorship W3186166064A5002095623 @default.
- W3186166064 hasAuthorship W3186166064A5029953659 @default.
- W3186166064 hasAuthorship W3186166064A5048130857 @default.
- W3186166064 hasAuthorship W3186166064A5049387929 @default.
- W3186166064 hasAuthorship W3186166064A5060985600 @default.
- W3186166064 hasAuthorship W3186166064A5070684364 @default.
- W3186166064 hasAuthorship W3186166064A5075954179 @default.
- W3186166064 hasAuthorship W3186166064A5077832560 @default.
- W3186166064 hasConcept C126322002 @default.
- W3186166064 hasConcept C143998085 @default.
- W3186166064 hasConcept C18031839 @default.
- W3186166064 hasConcept C197934379 @default.
- W3186166064 hasConcept C203014093 @default.
- W3186166064 hasConcept C2777938653 @default.
- W3186166064 hasConcept C2778375690 @default.
- W3186166064 hasConcept C2778461978 @default.
- W3186166064 hasConcept C2779338263 @default.
- W3186166064 hasConcept C2780653079 @default.
- W3186166064 hasConcept C71924100 @default.
- W3186166064 hasConceptScore W3186166064C126322002 @default.
- W3186166064 hasConceptScore W3186166064C143998085 @default.
- W3186166064 hasConceptScore W3186166064C18031839 @default.
- W3186166064 hasConceptScore W3186166064C197934379 @default.
- W3186166064 hasConceptScore W3186166064C203014093 @default.
- W3186166064 hasConceptScore W3186166064C2777938653 @default.
- W3186166064 hasConceptScore W3186166064C2778375690 @default.
- W3186166064 hasConceptScore W3186166064C2778461978 @default.
- W3186166064 hasConceptScore W3186166064C2779338263 @default.
- W3186166064 hasConceptScore W3186166064C2780653079 @default.
- W3186166064 hasConceptScore W3186166064C71924100 @default.
- W3186166064 hasFunder F4320307826 @default.
- W3186166064 hasFunder F4320308970 @default.
- W3186166064 hasLocation W31861660641 @default.
- W3186166064 hasLocation W31861660642 @default.
- W3186166064 hasOpenAccess W3186166064 @default.
- W3186166064 hasPrimaryLocation W31861660641 @default.
- W3186166064 hasRelatedWork W1799380558 @default.
- W3186166064 hasRelatedWork W1969480819 @default.
- W3186166064 hasRelatedWork W1971727742 @default.
- W3186166064 hasRelatedWork W2077606904 @default.
- W3186166064 hasRelatedWork W2121662877 @default.
- W3186166064 hasRelatedWork W2146425185 @default.
- W3186166064 hasRelatedWork W2883201369 @default.
- W3186166064 hasRelatedWork W3029070336 @default.
- W3186166064 hasRelatedWork W3115345348 @default.
- W3186166064 hasRelatedWork W3116220978 @default.
- W3186166064 hasVolume "111" @default.
- W3186166064 isParatext "false" @default.
- W3186166064 isRetracted "false" @default.
- W3186166064 magId "3186166064" @default.
- W3186166064 workType "article" @default.